Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;62(4):541-549.
doi: 10.1002/mus.27021. Epub 2020 Jul 31.

Diffusion tensor imaging reveals changes in non-fat infiltrated muscles in late onset Pompe disease

Affiliations

Diffusion tensor imaging reveals changes in non-fat infiltrated muscles in late onset Pompe disease

Robert Rehmann et al. Muscle Nerve. 2020 Oct.

Abstract

MRI is a helpful tool for monitoring disease progression in late-onset Pompe disease (LOPD). Our study aimed to evaluate if muscle diffusion tensor imaging (mDTI) shows alterations in muscles of LOPD patients with <10% fat-fraction. We evaluated 6 thigh and 7 calf muscles (both legs) of 18 LOPD and 29 healthy controls (HC) with muscle diffusion tensor imaging (mDTI), T1w, and mDixonquant sequences in a 3T MRI scanner. The quantitative mDTI-values axial diffusivity (λ1 ), mean diffusivity (MD), radial diffusivity (RD), and fractional anisotropy (FA) as well as fat-fraction were analyzed. 6-Minute Walk Test (6-MWT) data were correlated to diffusion metrics. We found that mDTI showed significant differences between LOPD and HC in diffusion parameters (P < .05). Thigh muscles with <10% fat-fraction showed significant differences in MD, RD, and λ1-3 . MD positively correlated with 6-MWT (P = .06). To conclude, mDTI reveals diffusion restrictions in muscles of LOPD with and without fat-infiltration and reflects structural changes prior to fatty degeneration.

Keywords: 6-Minute Walk Test; diffusion tensor imaging; glycogen storage disease type II; magnetic resonance imaging; muscle, skeletal; tractography.

PubMed Disclaimer

References

REFERENCES

    1. Lim JA, Li L, Raben N. Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci. 2014;6:1-14.
    1. Schüller A, Wenninger S, Strigl-pill N, Schoser B. Toward deconstructing the phenotype of late-onset Pompe disease. Am J Med Genet Part C. 2012;9:80-88.
    1. Carlier PG, Azzabou N, De Sousa PL, et al. Skeletal muscle quantitative nuclear magnetic resonance imaging follow-up of adult Pompe patients. J Inherit Metab Dis. 2015;38:565-572.
    1. Carlier RY, Laforet P, Wary C, et al. Whole-body muscle MRI in 20 patients suffering from late onset Pompe disease: involvement patterns. Neuromuscul Disord. 2011;21(11):791-799.
    1. Do HV, Khanna R, Gotschall R. Challenges in treating Pompe disease: an industry perspective. Ann Transl Med. 2019;7(13):291-291.

Publication types

LinkOut - more resources